This month, Xarelto was given the green light from the FDA and is now the first in its class approved for use in patients with existing coronary and/or peripheral artery disease to reduce the risk of major cardiovascular events like heart attack, stroke and cardiovascular death.
After this new approval, Xarelto can now be used for the following purposes:
- To reduce the risk of stroke and blood clots in people with atrial fibrillation, an irregular heart rate that can cause poor blood flow
- To treat deep vein thrombosis, a blood clot in the legs, and pulmonary embolism, a blood clot in the lungs
- To help prevent blood clots in the legs and lungs in those who have just had hip or knee replacement surgery
- To reduce the risk of major cardiovascular events like heart attack, stroke or death in those with coronary or peripheral artery disease
What are coronary and peripheral artery disease?
Peripheral artery disease is the narrowing of the arteries that supply blood to the legs, stomach, arms and head. See More